WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414648
CAS#: 937-13-3
Description: Oteracil is an antagonist of urate oxidase.
MedKoo Cat#: 414648
Name: Oteracil
CAS#: 937-13-3
Chemical Formula: C4H3N3O4
Exact Mass: 157.0124
Molecular Weight: 157.09
Elemental Analysis: C, 30.58; H, 1.93; N, 26.75; O, 40.74
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oteracil; Oxonic acid
IUPAC/Chemical Name: 1,3,5-Triazine-2-carboxylic acid, 1,4,5,6-tetrahydro-4,6-dioxo-
InChi Key: RYYCJUAHISIHTL-UHFFFAOYSA-N
InChi Code: InChI=1S/C4H3N3O4/c8-2(9)1-5-3(10)7-4(11)6-1/h(H,8,9)(H2,5,6,7,10,11)
SMILES Code: O=C(C(NC1=O)=NC(N1)=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 157.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). Oncologist. 2011;16(10):1451-7. doi: 10.1634/theoncologist.2011-0224. Epub 2011 Sep 30. PMID: 21963999; PMCID: PMC3228070.
2: Wang J, Wu DX, Meng L, Ji G. Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial. BMJ Open. 2020 Jun 3;10(6):e034685. doi: 10.1136/bmjopen-2019-034685. PMID: 32499264; PMCID: PMC7279648.
3: Park YJ, Soh BW, Lee ES. Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1). Eur J Dermatol. 2017 Apr 1;27(2):209-210. doi: 10.1684/ejd.2016.2953. PMID: 28251899.
4: Liu J, Wang C, Cao L, Li S. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. Ann Palliat Med. 2020 Mar;9(2):497-503. doi: 10.21037/apm.2020.03.14. Epub 2020 Mar 19. PMID: 32233637.
5: Kim J, Kim SH, Lee MG, Chung KY, Kim DS. Eccrine squamous syringometaplasia of underlying syringoma associated with Tegafur/Gimeracil/Oteracil (TS-1). Acta Derm Venereol. 2015 Nov;95(8):999-1000. doi: 10.2340/00015555-2092. PMID: 25766447.
6: Wang HF, Lv JQ. The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma. Cell Biochem Biophys. 2015 Jul;72(3):695-9. doi: 10.1007/s12013-015-0520-0. PMID: 25618173.
7: Tegafur + gimeracil + oteracil. Just another fluorouracil precursor. Prescrire Int. 2013 May;22(138):122. PMID: 23819172.
8: Ishizuna K, Ninomiya J, Ogawa T, Kojima M, Tsuji E, Kawashima M, Nozaki M, Yamagishi H, Ueda Y. Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study. Gan To Kagaku Ryoho. 2014 Dec;41(13):2577-82. PMID: 25596051.
9: Tsuda A, Fujiyama J, Miki A, Hori S, Ohtani H, Sawada Y. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Cancer Chemother Pharmacol. 2008 Aug;62(3):427-32. doi: 10.1007/s00280-007-0621-6. Epub 2007 Nov 17. PMID: 18026730.
10: Li F, Ju Y, Guan Y, Zhao H. [Tegafur gimeracil oteracil potassium capsule induced acute interstitial lung disease: a case report]. Zhongguo Fei Ai Za Zhi. 2014 Jan;17(1):53-6. Chinese. doi: 10.3779/j.issn.1009-3419.2014.01.09. PMID: 24398315; PMCID: PMC6000209.
